Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers

Japanese Journal of Clinical Oncology

Volumn 41, Issue 1, 2011, Pages 52-56

  Ogasawara, Naomi ^a   Bando, Hideaki ^a   Kawamoto, Yasuyuki ^a   Yoshino, Takayuki ^a   Tsuchihara, Katsuya ^a   Ohtsu, Atsushi ^a   Esumi, Hiroyasu ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

ARMS Scorpion method; Colorectal cancer; FFPE; KRAS mutation

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; K RAS PROTEIN; PARAFFIN;

ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA TEMPLATE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; REAL TIME POLYMERASE CHAIN REACTION;

COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; FIXATIVES; FORMALDEHYDE; GENE AMPLIFICATION; HUMANS; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 78650781323     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq151     Document Type: Article

References (9)

1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
2. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
3. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
5. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
6. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
7. Whitcombe D, Theaker J, Guy SP, Brown T, Little S. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 1999;17:804-7.
8. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
9. Williams C, Pontén F, Moberg C, Söderkvist P, Uhlén M, Pontén J, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999;155:1467-71.